Drug Patents owned by Genentech

1. List of Erivedge drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7888364 GENENTECH Pyridyl inhibitors of hedgehog signalling
Nov, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9790183 GENENTECH Pyridyl inhibitors of hedgehog signalling
Sep, 2025

(2 years from now)

US9278961 GENENTECH Pyridyl inhibitors of hedgehog signalling
Dec, 2028

(5 years from now)

Drugs and Companies using VISMODEGIB ingredient

Market Authorisation Date: 30 January, 2012

Treatment: Method of using vismodegib to treat basal cell carcinoma; Method of using vismodegib to treat cancer in a mammal

Dosage: CAPSULE;ORAL

More Information on Dosage

ERIVEDGE family patents

13

Korea, Republic of

9

United States

7

Australia

3

Japan

EA

3

EA

2

China

1

Poland

1

Canada

1

Slovenia

1

Ukraine

1

Luxembourg

1

Brazil

1

Denmark

1

Hungary

1

Spain

1

Mexico

1

New Zealand

1

Norway

1

South Africa

1

Austria

1

Portugal

1

Israel

1

Cyprus

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic